PARG and ovarian carcinoma: To determine whether PARG inhibitors might open up therapeutic opportunities in ovarian cancer, we assembled a panel of six ovarian cancer cell lines with genomic features that reflect HGSOC, namely Kuramochi, OVSAHO, COV362, COV318, CAOV3, and OVCAR3 (Figure S1A).